Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06849973 · ClinicalTrials.gov registry record · Phase 2
To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome
A Phase 2 study of Rett Syndrome, sponsored by Biomed Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 16
- Study locations
NCT06849973: Completed Phase 2 study of Rett Syndrome, sponsored by Biomed Industries.
NCT06849973 is a Phase 2 study of Rett Syndrome that has completed, run by Biomed Industries. The registered enrollment target is 187 participants, below the 515-participant average among 18 other Rett Syndrome trials with a reported enrollment target (64% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06849973, a Phase 2 study of Rett Syndrome, has completed, sponsored by Biomed Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 16
- Study locations
Study Summary
To study the efficacy \& safety of oral Bionetide versus placebo in girls and women with Rett syndrome
Primary Outcome
The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the tota
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Drug: Bionetide
Study Locations (16)
California
- Biomed Testing Facility # BIO-04-92093 - La Jolla
- Biomed Testing Facility # BIO-03-90095 - Los Angeles
- Biomed Testing Facility # BIO-02-95817 - Sacramento
- Biomed Testing Facility # BIO-01-94104 - San Francisco
New South Wales
- Biomed Research Unit-BIO-16-NSW - Camperdown
- Biomed Research Unit-BIO-15 - Sydney
Victoria
- Biomed Research Unit-BIO-13-VIC-3084 Heidelberg West, Victoria, Australia, 3084 - Heidelberg West
- Biomed Research Unit- BIO-14-VIC 3010 - Parkville
Colorado
- Biomed Testing Facility #BIO-05-80042 - Aurora
Illinois
- Biomed Testing Facility #BIO-06-60612 - Chicago
Maryland
- Maryland Locations Biomed Testing Facility #BIO-7-21205 - Baltimore
Massachusetts
- Biomed Testing Facility #BIO-8-02115 - Boston
New York
- Biomed Testing Facility #BIO-9-10467 - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 2 |
What the finished NCT06849973 record still lists
NCT06849973 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 515-participant average among 18 other Rett Syndrome trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06849973 lists 16 locations in 11 states (California, New South Wales, Victoria).
Frequently Asked Questions
What is clinical trial NCT06849973 about?
NCT06849973 is a clinical study titled "To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome". To study the efficacy \& safety of oral Bionetide versus placebo in girls and women with Rett syndrome
What is the current status of trial NCT06849973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2024-03-15. Estimated completion is 2025-01-28.
What conditions does trial NCT06849973 study?
This clinical trial studies the following conditions: Rett Syndrome.
What interventions are being tested in trial NCT06849973?
The interventions under investigation include: Placebo (DRUG), Drug: Bionetide (DRUG).
Who is sponsoring clinical trial NCT06849973?
This trial is sponsored by Biomed Industries, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06849973 being conducted?
This trial has 16 study locations across California, Colorado, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rett Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06849973's enrollment target sits among peer trials
187 6th of 18 higher than 13 of 18 other Rett Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rett Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Placebo Controlled Trial of Dextromethorphan in Rett Syndrome
COMPLETED · Phase 2
-
Rett Syndrome Registry
RECRUITING
-
Cognitive Function in Rett Syndrome During Trofinetide Treatment
RECRUITING
-
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
RECRUITING
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI